Helixstreet based in Basel is developing a DNA analytics platform based on a combination of distributed technologies with machine learning. In the pharma industry, the platform will set the foundation for developing personalized medicine. Helixstreet has joined the NVIDIA Inception program to develop the technology further.
NVIDIA is the leading provider of high-end graphics processing units (GPUs) used for competitive gaming, professional visualization, and cryptocurrency mining. Last year, Nvidia reported record revenues of $9.71 billion. Through its Inception program, Nvidia offers early stage and later stage promising startups that use cutting-edge deep learning and AI technology with a virtual accelerator to accelerate their development. The program provides go-to-market support, expertise, and technology through deep learning training, exclusive Inception events, GPU discounts among others.
One of the selected startups in the current cohort is Helixstreet, the first DNA Analytics company based at the Technologiepark in Basel. As part of the NVIDIA program, Helixstreet will additionally receive a computing credit for up to USD $100’000 for the Amazon Cloud computing platform to support the development of its deep learning framework.
Founded in 2017 by a team of IT specialists, Helixstreet is focused on the development of Long Read Sequencing and Deep Learning technology by combining Blockchain technology, the latest DNA Sequencing Technology (such as 3rd generation Sequencing and Long Read Sequencing) together with machine learning to analyse DNA. This approach allows the platform to detect new undiscovered structural variants in the human genome and grouping DNA into helixgroups, a feature that is envisioned to be the foundation for targeted and personalized medicine.
The startup also seeks to empower individuals to take ownership of their genomic data. Through the helixstreet app, individuals can store their DNA in several electronic patient dossiers (EPD) which will enable doctors to establish diagnosis faster. Target customers include individuals who want to discover their genetic code and the pharma industry, which may use the AI platform to develop new drugs.
The startup is currently in the early development phase and one of its achievements was the development of a deep learning algorithm, which detects a trait completely based on unsupervised deep learning in the human genome.
0Comments
Please login or sign up to comment.
Commenting guidelines